LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems

被引:424
作者
Grosso, Joseph F.
Kelleher, Cristin C.
Harris, Timothy J.
Maris, Charles H.
Hipkiss, Edward L.
De Marzo, Angelo
Anders, Robert
Netto, George
Getnet, Derese
Bruno, Tullia C.
Goldberg, Monica V.
Pardoll, Drew M.
Drake, Charles G.
机构
[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
关键词
D O I
10.1172/JCI31184
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Lymphocyte activation gene-3 (LAG-3) is a cell-surface molecule with diverse biologic effects on T cell function. We recently showed that LAG-3 signaling is important in CD4(+) regulatory T cell suppression of autoimmune responses. Here, we demonstrate that LAG-3 maintains tolerance to self and tumor antigens via direct effects on CD8(+) T cells using 2 murine systems. Naive CD8(+) T cells express low levels of LAG-3, and expression increases upon antigen stimulation. Our data show increased levels of LAG-3 protein on antigen-specific CD8(+) T cells within antigen-expressing organs or tumors. In vivo antibody blockade of LAG-3 or genetic ablation of the Lag-3 gene resulted in increased accumulation and effector function of antigen-specific CD8(+) T cells within organs and tumors that express their cognate antigen. Most notably, combining LAG-3 blockade with specific antitumor vaccination resulted in a significant increase in activated CD8(+) T cells in the tumor and disruption of the tumor parenchyma. A major component of this effect was CD4 independent and required LAG-3 expression by CD8(+) T cells. Taken together, these data demonstrate a direct role for LAG-3 on CD8(+) T cells and suggest that LAG-3 blockade may be a potential cancer treatment.
引用
收藏
页码:3383 / 3392
页数:10
相关论文
共 53 条
  • [31] Morgan DJ, 1996, J IMMUNOL, V157, P978
  • [32] *NORM GREENB LAB, VID INSTR MAN GUID
  • [33] T-cell tolerance or function is determined by combinatorial costimulatory signals
    Nurieva, Roza
    Thomas, Sunil
    Nguyen, Thang
    Martin-Orozco, Natalia
    Wang, Ying
    Kaja, Murali-Krishna
    Yu, Xue-Zhong
    Dong, Chen
    [J]. EMBO JOURNAL, 2006, 25 (11) : 2623 - 2633
  • [34] Does the immune system see tumors as foreign or self?
    Pardoll, D
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2003, 21 : 807 - 839
  • [35] Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis
    Rodig, N
    Ryan, T
    Allen, JA
    Pang, H
    Grabie, N
    Chernova, T
    Greenfield, EA
    Liang, SC
    Sharpe, AH
    Lichtman, AH
    Freeman, GJ
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (11) : 3117 - 3126
  • [36] Rosenberg SA, 2003, CLIN CANCER RES, V9, P2973
  • [37] In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
    Shin, T
    Yoshimura, K
    Shin, T
    Crafton, EB
    Tsuchiya, H
    Housseau, F
    Koseki, H
    Schulick, RD
    Chen, LP
    Pardoll, DM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (10) : 1531 - 1541
  • [38] Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
    Small, Eric J.
    Schellhammer, Paul F.
    Higano, Celestia S.
    Redfern, Charles H.
    Nemunaitis, John J.
    Valone, Frank H.
    Verjee, Suleman S.
    Jones, Lori A.
    Hershberg, Robert M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3089 - 3094
  • [39] Therapeutic cancer vaccines
    Srivastava, PK
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (02) : 201 - 205
  • [40] TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
    Thomas, DA
    Massagué, J
    [J]. CANCER CELL, 2005, 8 (05) : 369 - 380